Refractory Mycosis Fungoides Clinical Trial
Official title:
Prospective Observational Trial of Low-Dose Total Skin Electron Therapy in Mycosis Fungoides Using Rotisserie Technique
This clinical trial studies low- dose total skin electron therapy in treating patients with stage IB-IIIA mycosis fungoides that has not responded to previous treatment (refractory) or has returned after a period of improvement (relapsed). Radiation therapy uses high energy electrons to kill tumor cells and shrink tumors. Rotisserie technique is a method in which the patient receives total skin electron therapy while standing on a rotating platform. Giving low dose total skin electron therapy using rotisserie technique may kill tumor cells, while having fewer side effects, and may allow therapy to be repeated in future if clinically indicated.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | September 2026 |
Est. primary completion date | September 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Biopsy confirmed mycosis fungoides stage IB-IIIA - Skin manifestations of mycosis fungoides that are refractory to or have relapsed on at least one prior therapy, which may include topical steroids - Life expectancy > 6 months Exclusion Criteria: - Serious medical condition that would make treatment unsafe - Pregnant or lactating patient |
Country | Name | City | State |
---|---|---|---|
United States | Vanderbilt-Ingram Cancer Center | Nashville | Tennessee |
Lead Sponsor | Collaborator |
---|---|
Vanderbilt-Ingram Cancer Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in skin-related quality of life assessed by Skindex-29 | Skindex-29 is a validated quality of life questionnaire to help quantify how mycosis fungoides may affect one's quality of life on a day to day basis, including emotional impact of the skin disease. | Baseline to up to 3 years | |
Secondary | Change in the durability of response assessed by mSWAT tool | mSWAT is the Modified Severity Weighted Assessment Tool used by the radiation oncologist during complete physical examination to quantify skin findings of patches, plaques, and tumors in all regions of the body; this would help the radiation oncologist and dermatologist to better follow the response to treatment. | Baseline to up to 3 years | |
Secondary | Incidence of side effects of low dose total skin electron therapy administered via rotisserie technique | The patient will be closely monitored by the radiation oncologist during treatment, with at least 2-3 visits while patient is on treatment. Side effects will be documents in patient medical records. | Up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02978625 -
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
|
Phase 2 | |
Active, not recruiting |
NCT03278782 -
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
|
Phase 1/Phase 2 | |
Completed |
NCT03281811 -
Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides
|
Early Phase 1 | |
Terminated |
NCT03075553 -
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT03011814 -
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
|
Phase 1/Phase 2 | |
Suspended |
NCT03432741 -
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
|
Phase 1 | |
Withdrawn |
NCT03373305 -
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04074746 -
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03598998 -
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04541017 -
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
|
Phase 1/Phase 2 | |
Recruiting |
NCT03017820 -
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
|
Phase 1 |